| Identification | Back Directory | [Name]
ISOLIQUIRITIN | [CAS]
5041-81-6 | [Synonyms]
Aids004475
Aids-004475
ISOLIQUIRITIN
neoisoliquritin
Isoliquiritoside
2',4,4'-Trihydroxychalcone 4-beta-D-glucopyranoside
2',4,4'-Trihydroxychalcone 4-(beta-D-glucopyranoside)
[(E)-2',4'-Dihydroxychalcone-4-yl]β-D-glucopyranoside
(E)-1-(2,4-Dihydroxyphenyl)-3-[4-(β-D-glucopyranosyloxy)phenyl]-2-propen-1-one
4-[(1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl beta-D-glucopyranoside
2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (2E)- | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C21H22O9 | [MDL Number]
MFCD00272145 | [MOL File]
5041-81-6.mol | [Molecular Weight]
418.39 |
| Chemical Properties | Back Directory | [Melting point ]
185-186℃ | [Boiling point ]
743.5±60.0 °C(Predicted) | [density ]
1.528 | [storage temp. ]
4°C, protect from light | [solubility ]
Soluble in methan | [form ]
powder | [pka]
7.46±0.35(Predicted) | [color ]
Ochre | [biological source]
plant | [Major Application]
metabolomics
vitamins, nutraceuticals, and natural products | [InChI]
InChI=1/C21H22O9/c22-10-17-18(26)19(27)20(28)21(30-17)29-13-5-1-11(2-6-13)3-8-15(24)14-7-4-12(23)9-16(14)25/h1-9,17-23,25-28H,10H2/b8-3+/t17-,18-,19+,20-,21-/s3 | [InChIKey]
YNWXJFQOCHMPCK-RQOZFYCLNA-N | [SMILES]
[C@@H]1([C@H](O)[C@H]([C@H](O)[C@@H](CO)O1)O)OC1=CC=C(/C=C/C(=O)C2C=CC(O)=CC=2O)C=C1 |&1:0,1,3,4,6,r| |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from licorice. | [Uses]
It is a natural product derived from plant source th at finds application in compound screening libraries, metabolomics, phytochemical, and pharmaceutical research. | [Definition]
ChEBI: A monosaccharide derivative that is trans-chalcone substituted by hydroxy groups at positions 2' and 4' and a beta-D-glucopyranosyloxy group at position 4 respectively. | [Biological Activity]
Isoliquiritin triggers apoptotic cell death by increasing the levels of p53 and p21 in A549 non-small cell lung cancer cells while also inhibiting the p53-dependent pathway and revealing interactions with Akt activities. FutherIsoliquiritin has demonstrated neuroprotective activity against oxidative stress and has the capability to restrain the growth of microbial pathogens. | [in vivo]
Isoliquiritin (0.31-3.1 mg/kg, i.p., once a day for 5 days) inhibits granuloma angiogenesis in mice[1].
Isoliquiritin (10-40 mg/kg, oral gavage) shows antidepressant-like effects in FST and TST tests in mice[2].
Isoliquiritin ((10 mg/kg/bw/day, p.o.) shows anti-oxidative and anti-Inflammatory properties, and relieves cationic BSA-Induced membranous glomerulonephritis in experimental rat model[5].
| Animal Model: | Mice in Forced Swimming Test (FST) and the Tail Suspension Test (TST)[2] | | Dosage: | 10, 20 and 40 mg/kg | | Administration: | oral gavage | | Result: | Reduced the immobility time in the FST and TST in mice.
Increased 5-HT and NE level and Reduced the ratio of 5-HIAA/5-HT in the hippocampus, hypothalamus and cortex. |
| [target]
HIV | [storage]
4°C, protect from light |
|
|